COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones.
TORONTO, ON / ACCESS Newswire / January 8, 2026 / Inventus Mining Corp. (TSXV:IVS) ("Inventus" or the "Company")is ...
MarketBeat on MSN
3 stocks that benefit if companies cut costs in 2026
We are entering a new earnings season. Earnings reports are crucial to understanding a company’s outlook for revenue and ...
AWS AI leadership, Anthropic stake, and ad growth support upside despite capex. Click for an updated look at AMZN stock ...
Q4 2025 Earnings Call Transcript January 8, 2026 TD SYNNEX Corporation beats earnings expectations. Reported EPS is $3.83, ...
G&A Expense -- $1.9 million, down from $2.3 million mainly due to lower compensation and recruitment spending. Cash on ...
Market Intelligence analyst Jeff Lipton, in the second installment of his three-part 2026 outlook series, maps out quality-centric portfolio shifts, barbell and long-end strategies, and sector tilts ...
Any repurchases will be funded from the Company’s existing cash balances, future operating cash flows, or other legally available funds. Repurchases will be conducted in accordance with the Company’s ...
Piedmont Realty Trust (PDM) looks deeply undervalued at 5.2x P/FFO, with $14.50 fair value and 2026 dividend return potential ...
“At the heart of the scheme, Drake—acting directly and through willing and knowledgeable co-conspirators—has deployed ...
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...
These are the top stocks that gained the attention of retail traders and investors throughout the day. Nio’s stock climbed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback